- Home
- REPX vs ATXS Comparison
REPX vs ATXS Comparison
Compare REPX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- ATXS
- Stock Information
- Founded
- REPX 2016
- ATXS 2008
- Country
- REPX United States
- ATXS United States
- Employees
- REPX N/A
- ATXS N/A
- Industry
- REPX Oil & Gas Production
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- REPX Energy
- ATXS Health Care
- Exchange
- REPX Nasdaq
- ATXS Nasdaq
- Market Cap
- REPX 581.0M
- ATXS 676.1M
- IPO Year
- REPX N/A
- ATXS 2015
- Fundamental
- Price
- REPX $26.41
- ATXS $12.50
- Analyst Decision
- REPX Strong Buy
- ATXS Buy
- Analyst Count
- REPX 2
- ATXS 7
- Target Price
- REPX $41.50
- ATXS $30.00
- AVG Volume (30 Days)
- REPX 128.7K
- ATXS 4.1M
- Earning Date
- REPX 11-05-2025
- ATXS 11-12-2025
- Dividend Yield
- REPX 5.81%
- ATXS N/A
- EPS Growth
- REPX N/A
- ATXS N/A
- EPS
- REPX 4.52
- ATXS N/A
- Revenue
- REPX $392,885,000.00
- ATXS N/A
- Revenue This Year
- REPX N/A
- ATXS N/A
- Revenue Next Year
- REPX $8.97
- ATXS N/A
- P/E Ratio
- REPX $5.78
- ATXS N/A
- Revenue Growth
- REPX N/A
- ATXS N/A
- 52 Week Low
- REPX $21.98
- ATXS $3.56
- 52 Week High
- REPX $37.55
- ATXS $12.60
- Technical
- Relative Strength Index (RSI)
- REPX 42.08
- ATXS 83.50
- Support Level
- REPX $26.04
- ATXS $12.40
- Resistance Level
- REPX $27.44
- ATXS $12.60
- Average True Range (ATR)
- REPX 0.91
- ATXS 0.28
- MACD
- REPX -0.11
- ATXS 0.10
- Stochastic Oscillator
- REPX 11.96
- ATXS 97.37
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.